The	0	3	O
contribution	4	16	O
of	17	19	O
Harold	20	26	O
F	27	28	O
.	28	29	O
Dvorak	30	36	O
to	37	39	O
the	40	43	O
study	44	49	O
of	50	52	O
tumor	53	58	B-Pathological_formation
angiogenesis	59	71	O
and	72	75	O
stroma	76	82	B-Tissue
generation	83	93	O
mechanisms	94	104	O
.	104	105	O

In	107	109	O
1983	110	114	O
,	114	115	O
Harold	116	122	O
Dvorak	123	129	O
and	130	133	O
his	134	137	O
colleagues	138	148	O
were	149	153	O
the	154	157	O
first	158	163	O
to	164	166	O
show	167	171	O
that	172	176	O
tumor	177	182	B-Cell
cells	183	188	I-Cell
secreted	189	197	O
vascular	198	206	B-Gene_or_gene_product
permeability	207	219	I-Gene_or_gene_product
factor	220	226	I-Gene_or_gene_product
(	227	228	O
VPF	228	231	B-Gene_or_gene_product
)	231	232	O
and	233	236	O
that	237	241	O
a	242	243	O
blocking	244	252	O
antibody	253	261	O
to	262	264	O
VPF	265	268	B-Gene_or_gene_product
could	269	274	O
prevent	275	282	O
the	283	286	O
edema	287	292	B-Pathological_formation
and	293	296	O
fluid	297	302	O
accumulation	303	315	O
that	316	320	O
is	321	323	O
characteristic	324	338	O
of	339	341	O
human	342	347	B-Organism
cancers	348	355	B-Pathological_formation
.	355	356	O

In	357	359	O
1986	360	364	O
,	364	365	O
Dvorak	366	372	O
went	373	377	O
on	378	380	O
to	381	383	O
demonstrate	384	395	O
that	396	400	O
VPF	401	404	B-Gene_or_gene_product
was	405	408	O
secreted	409	417	O
by	418	420	O
a	421	422	O
variety	423	430	O
of	431	433	O
human	434	439	B-Organism
tumor	440	445	B-Cell
cell	446	450	I-Cell
lines	451	456	I-Cell
and	457	460	O
proposed	461	469	O
that	470	474	O
VPF	475	478	B-Gene_or_gene_product
was	479	482	O
in	483	485	O
part	486	490	O
responsible	491	502	O
for	503	506	O
the	507	510	O
abnormal	511	519	O
vasculature	520	531	B-Multi-tissue_structure
seen	532	536	O
in	537	539	O
human	540	545	B-Organism
tumors	546	552	B-Pathological_formation
.	552	553	O

As	554	556	O
a	557	558	O
result	559	565	O
,	565	566	O
he	567	569	O
and	570	573	O
other	574	579	O
investigators	580	593	O
demonstrated	594	606	O
that	607	611	O
VPF	612	615	B-Gene_or_gene_product
was	616	619	O
capable	620	627	O
of	628	630	O
stimulating	631	642	O
endothelial	643	654	B-Cell
cell	655	659	I-Cell
growth	660	666	O
and	667	670	O
angiogenesis	671	683	O
.	683	684	O

These	685	690	O
fundamental	691	702	O
discoveries	703	714	O
led	715	718	O
to	719	721	O
additional	722	732	O
research	733	741	O
conducted	742	751	O
by	752	754	O
Napoleone	755	764	O
Ferrara	765	772	O
and	773	776	O
his	777	780	O
laboratory	781	791	O
,	791	792	O
confirming	793	803	O
the	804	807	O
cloning	808	815	O
of	816	818	O
VPF	819	822	B-Gene_or_gene_product
and	823	826	O
renaming	827	835	O
the	836	839	O
protein	840	847	O
vascular	848	856	B-Gene_or_gene_product
endothelial	857	868	I-Gene_or_gene_product
growth	869	875	I-Gene_or_gene_product
factor	876	882	I-Gene_or_gene_product
(	883	884	O
VEGF	884	888	B-Gene_or_gene_product
)	888	889	O
.	889	890	O

In	891	893	O
1986	894	898	O
,	898	899	O
Dvorak	900	906	O
proposed	907	915	O
that	916	920	O
by	921	923	O
secreting	924	933	O
VPF	934	937	B-Gene_or_gene_product
,	937	938	O
tumors	939	945	B-Pathological_formation
induce	946	952	O
angiogenesis	953	965	O
by	966	968	O
turning	969	976	O
on	977	979	O
the	980	983	O
wound	984	989	O
healing	990	997	O
response	998	1006	O
.	1006	1007	O

He	1008	1010	O
noted	1011	1016	O
that	1017	1021	O
wounds	1022	1028	O
,	1028	1029	O
like	1030	1034	O
tumors	1035	1041	B-Pathological_formation
,	1041	1042	O
secrete	1043	1050	O
VPF	1051	1054	B-Gene_or_gene_product
,	1054	1055	O
causing	1056	1063	O
blood	1064	1069	B-Multi-tissue_structure
vessels	1070	1077	I-Multi-tissue_structure
to	1078	1080	O
leak	1081	1085	O
plasma	1086	1092	B-Organism_substance
fibrinogen	1093	1103	B-Gene_or_gene_product
,	1103	1104	O
which	1105	1110	O
stimulates	1111	1121	O
blood	1122	1127	B-Multi-tissue_structure
vessel	1128	1134	I-Multi-tissue_structure
growth	1135	1141	O
and	1142	1145	O
provides	1146	1154	O
a	1155	1156	O
matrix	1157	1163	O
on	1164	1166	O
which	1167	1172	O
they	1173	1177	O
can	1178	1181	O
spread	1182	1188	O
.	1188	1189	O

Unlike	1190	1196	O
wounds	1197	1203	O
,	1203	1204	O
however	1205	1212	O
,	1212	1213	O
that	1214	1218	O
turn	1219	1223	O
off	1224	1227	O
VPF	1228	1231	B-Gene_or_gene_product
production	1232	1242	O
after	1243	1248	O
healing	1249	1256	O
,	1256	1257	O
tumors	1258	1264	B-Pathological_formation
did	1265	1268	O
not	1269	1272	O
turn	1273	1277	O
off	1278	1281	O
their	1282	1287	O
VPF	1288	1291	B-Gene_or_gene_product
production	1292	1302	O
and	1303	1306	O
instead	1307	1314	O
continued	1315	1324	O
to	1325	1327	O
make	1328	1332	O
large	1333	1338	O
amounts	1339	1346	O
of	1347	1349	O
VPF	1350	1353	B-Gene_or_gene_product
,	1353	1354	O
allowing	1355	1363	O
malignant	1364	1373	B-Cell
cells	1374	1379	I-Cell
to	1380	1382	O
continue	1383	1391	O
to	1392	1394	O
induce	1395	1401	O
new	1402	1405	O
blood	1406	1411	B-Multi-tissue_structure
vessels	1412	1419	I-Multi-tissue_structure
and	1420	1423	O
so	1424	1426	O
to	1427	1429	O
grow	1430	1434	O
and	1435	1438	O
spread	1439	1445	O
.	1445	1446	O

Thus	1447	1451	O
,	1451	1452	O
tumors	1453	1459	B-Pathological_formation
behave	1460	1466	O
like	1467	1471	O
wounds	1472	1478	O
that	1479	1483	O
fail	1484	1488	O
to	1489	1491	O
heal	1492	1496	O
.	1496	1497	O

This	1498	1502	O
work	1503	1507	O
is	1508	1510	O
again	1511	1516	O
extremely	1517	1526	O
significant	1527	1538	O
for	1539	1542	O
patients	1543	1551	B-Organism
worldwide	1552	1561	O
,	1561	1562	O
as	1563	1565	O
Dvorak	1566	1572	O
'	1572	1573	O
s	1573	1574	O
scientific	1575	1585	O
research	1586	1594	O
is	1595	1597	O
leading	1598	1605	O
his	1606	1609	O
colleagues	1610	1620	O
all	1621	1624	O
over	1625	1629	O
the	1630	1633	O
world	1634	1639	O
to	1640	1642	O
examine	1643	1650	O
how	1651	1654	O
to	1655	1657	O
treat	1658	1663	O
a	1664	1665	O
tumor	1666	1671	B-Pathological_formation
through	1672	1679	O
its	1680	1683	O
blood	1684	1689	B-Organism_substance
supply	1690	1696	O
.	1696	1697	O

